A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule

REFERENCES

• SONNENBERG A, EVERHART JE: Health impact of peptic ulcer in the United States. Am. J. Gastreenterel. (1997) 92:614–620.
   PubMed Web of Science ®Google Scholar
• INADOMI JM, SONNENBERG A: The impact of peptic ulcer disease and infection with Hellen/tarter pylori on life expectancy. Am. J. Gastmenterel. (1998) 93:1286–1290.
   PubMed Web of Science ®Google Scholar
• DE BOER WA, JOOSEN EAM: Disease management of dyspepsia. Scant/. j. Gastreenterel. (1999) 34\(Suppl. 230):23–28.
   Google Scholar
• ANONYMOUS: Current European concepts in the management of Hellen/tarter pylori infection. The Maastricht Consensus report. Gut (1997) 41:8–13.
   PubMed Web of Science ®Google Scholar
• •Major European clinical guideline.
   Google Scholar
• LAM SK, TALLEY NJ: Report of the 1997 Asia Pacific Consensus Conference on the management of Hellen/tarter pylori infection. Gastreenterel. Hepatel. (1998)13:1–12.
   PubMed Web of Science ®Google Scholar
• •Major Asian clinical guideline.
   Google Scholar
• HOWDEN CW, HUNT RH. AGA: Practice guidelines. Guidelines for the management of Hellen/tarter pylori infection. Am. J. Gastmenterel. (1998) 93:2330–2338.
   PubMed Web of Science ®Google Scholar
• •Major American clinical guideline.
   Google Scholar
• DE BOER WA, TYTGAT GNJ: Search and treat strategy to eliminate Hellen/tarter pylori associated ulcer disease. Gut (2001) 48:567–570.
   PubMed Web of Science ®Google Scholar
• MOAYEDDI P, SOO S, DEEKS J et al.: Systematic review and economic evaluation of Hellen/tarter pylori eradication treatment for non-ulcer dyspepsia. BMJ(2000) 321:659–664.
   PubMed Web of Science ®Google Scholar
• •Important meta-analysis.
   Google Scholar
• SCHWIZER W, THUMSHIRN M, DENT J et al.: Hellen/tarter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet (2001) 357:1738–1742.
   PubMed Web of Science ®Google Scholar
• KUIPERS EJ, LUNDELL L, KLINKENBERG-KNOL EC et al.: Atrophic gastritis and Hellen/tarter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl. j. Med. (1996) 334:1018–1022.
   PubMed Web of Science ®Google Scholar
• LASSEN AT, PEDERSEN FM, BYTZER P,SCHAFFALITZKY DE MUCKADELL OB: Hellen/tarter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet (2000) 356:455–460.
   PubMed Web of Science ®Google Scholar
• VELDHUYZEN VAN ZANTEN SJO, FLOOK N, CHIBA N et al.: An evidence-based approach to the management of uninvestigated dyspepsia in the era of Hellen/tarterCMAJ(2000) 162\(Suppl.12):S3–S23.
   Google Scholar
• BOWIE PES, COX RA, DAVIDSON AR, STEEL A: Young dyspeptic patients: with a test-and-treat policy, are the benefits of decreased symptom severity and oesophago-gastro-duodenoscopy workload sustained? Eur. j Gastreenterel. Hepatel. (2001) 13:541–545.
   PubMed Web of Science ®Google Scholar
• MARSHALL BJ, WARREN JR: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (1984) i:1311–1315.
   Google Scholar
• LAHEY RJF, VAN ROOSUM LGM, JANSEN JBMJ, STRAATMAN H, VERBEEK ALM: Evaluation of treatment regimens to cure Hellen/tarter pylori infection - a meta-analysis. Aliment PharmaceL Titer. (1999) 13:857–864.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis of treatment regimens.
   Google Scholar
• HOUBEN MHMG, VAN DE BEEK D, HENSEN EF, DE CRAEN AJM, RAUWS EAJ, TYTGAT GNJ: A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Ailment Pharmacy]. Ther. (1999) 13:1047-1055. Meta-analysis of impact of resistance on cure rates.
   Google Scholar
• GRAHAM DY: Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology (1998) 115:1272–1277.
   PubMed Web of Science ®Google Scholar
• BORODY TJ, CARRICK J, HAZELL SL: Symptoms improve after the eradication of gastric Campylobacter pyloridis. Med Austr. (1987) 146:450–451.
   PubMed Web of Science ®Google Scholar
• BORODY TJ, COLE P, NOONAN S et al.: Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med j Austr: (1989) 151:431–435.
   PubMed Web of Science ®Google Scholar
• VAN DER HULST RWM, KELLER JJ, RAUWS EAJ, TYTGAT GNJ: Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter (1996) 1:6–19.
   PubMedGoogle Scholar
• TREIBER G: The influence of drug dosageon Helicobacter pylori eradication: a cost-effectiveness analysis. Am. I Gastroenterol. (1996) 91:246–257.
   PubMed Web of Science ®Google Scholar
• PENSTON JG, McCOLL KEL: Eradication of Helicobacter pylori: an objective assessment of current therapies. Br. Pharmacol. (1997) 43:223–243.
   Web of Science ®Google Scholar
• WANG WH, WONG BCY, LAM SK: Pooled analysis of Helicobacter pylori eradication regimens in Asia. Gastroenterol. Hepatol. (2000) 15:1007–1017.
   Google Scholar
• BOEKEMA PJ, VEENENDAAL RA, VANBERGE-HENEGOUWEN GP: After a decade of Helicobacter pylori in the Netherlands. A survey of the practice of the members of the Dutch Society of Gastroenterology. Neth. j Med. (1997) 51:129–133.
   Google Scholar
• BREUER T, MALATY HM, GOODMAN K, SUDHOP T, GRAHAM DY: Treatment regimens used in Helicobacter pylori positive ulcer disease; a nationwide comparison of gastroenterologists and family practitioners in the United States of America. Gut (1996) 39\(Suppl. 2):A22.
   Google Scholar
• DE BOER WA: Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur. Gastroenterol. Hepatol. (1999) 11:697–700.
   PubMed Web of Science ®Google Scholar
• RODION OFF E HYLAND L, OSTAPOWICZ N et al.: Triple therapy for Helicobacter pylori eradication - 1,2 or 4 weeks? World Congress of Gastroenterology, Sydney, Australia, August 26–31 (1990) (Abstract PP938).
   Google Scholar
• DE BOER WA, DRIESSEN WMM, POTTERS HVPJ, TYTGAT GNJ: Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating H pylori. Am. j Gastroenterol. (1994) 89:1993–1997.
   PubMed Web of Science ®Google Scholar
• NOACH LA, LANGENBERG WL, BERTOLA MA, DANKERT J, TYTGAT GNJ: Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scam/. Infect. Dis. (1994) 26:321–327.
   PubMed Web of Science ®Google Scholar
• DE BOER WA, TYTGAT GNJ: How to treat Helicobacter pylori infection. Should treatment strategies be based on testing bacterial susceptibility? Eur. j Gastroenterol. Hepatol. (1996) 8:709–716.
   PubMed Web of Science ®Google Scholar
• DE BOER WA, DRIESSEN WMM, JANSZ AR, TYTGAT GNJ: Effect of acid suppression on efficacy of treatment for Helicobacter pylori Lancet (1995) 345:817–820.
   Google Scholar
• DESKALOPOULOS G, CARRICK J, LIAN R, LEE A: Optimising therapy for H pylori gastritis. Ir. J. Med Sci. (1992) 161\(Suppl. 10):16.
   Google Scholar
• BORODY TJ, ANDREWS E FRACCHIA G, BRANDL S, SHORTIS NP, BAE H: Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori Gut (1995) 37:477–481.
   Google Scholar
• CHAN FKL, YUNG MY, LING TKW, LEUNG WK, CHUNG SCS: What is the true impact of metronidazole resistance on the efficacy of bismuth triple therapy? Gut (1998) 43\(Suppl. 2):A85.
   Google Scholar
• CHIBA N, HUNT RH: Bismuth, metronidazole and tetracycline (BMT)+ acid suppression in H pylori eradication: a meta-analysis. Gut (1996) 39\(Suppl. 2):A36–A37.
   Google Scholar
• BORODY TJ, ANDREWS E SHORTIS NP, HYLAND I: Seven day therapy for Helicobacter pylori (abstract) Gastroenterology (1995) 108:A62.
   Google Scholar
• TEFERA S, BERSTAD A, BANG CJ et al: Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain. Am. j Gastroenterol. (1996) 91:935–941.
   PubMed Web of Science ®Google Scholar
• HOSKING SW, LING TKW, CHUNG SCS et al: Duodenal ulcer healing by eradication of H pylori without anti-acid treatment. Randomised controlled trial. Lancet (1994) 343:508–510.
   PubMed Web of Science ®Google Scholar
• DE BOER WA, VAN ETTEN RJXM, SCHNEEBERGER PM: Four-day Lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. Neth. J Med. (1998) 52:10–15.
   PubMed Web of Science ®Google Scholar
• MEGRAUD F: Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori Gastroenterology (1998) 115:1278–1282.
   PubMed Web of Science ®Google Scholar
• CABRITA J, OLEASATRO M, MATOS R et al.: Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990–1999). 1 Aritimicrob. Chemother. (2000) 46:1029–1031.
   Google Scholar
• DEKOSTER E, DEVASTER JM, VANDENBORRE C, DELAUNOIT T, LANGLET P, DELTENRE M: A nine years surveillance of HP resistance to macrolides and imidazoles. Gastroenterology (1999) 116:A145.
   Web of Science ®Google Scholar
• LAINE L, MALONE T, BOCHENEK W, WANG W, OSATO M: Current US rates of H pylori antibiotic resistance and factors predicting resistance: results from ongoing trials at 77 sites. Gastroenterology (1999) 116:A228.
   Web of Science ®Google Scholar
• FOCK KM: Clarithromycin resistance inH pylori infection: Does it matter? Gastroenterol. Hepatol. (2000) 15:1089–1092.
   Web of Science ®Google Scholar
• WANG WH, WONG BCY, MUKHOPADHYAY AK et al: High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol. Ther. (2000) 14:901–910.
   PubMed Web of Science ®Google Scholar
• MITCHELL HM, BRUSENTSEV S, HAZELL SL, BORODY TJ, DESKALOPOULOS G, BRADBEAR R: A high level of primary resistance to metronidazole and clarithromycin in previously untreated symptomatic patients presenting for endoscopy in Australia. Gut (2000) 47\(Suppl. 1):A107.
   Google Scholar
• RUBIN GP, MEINECHE-SCHMIDT V, ROBERTS AE CHILDS SM, DE WIT NJ: The management of Helicobacter pylori infection in primary care. Guidelines from the ESPCG. Eur. I Gen. Pract. (1999) 5:98–104.
   Google Scholar
• •Major European primary care practice guideline.
   Google Scholar
• DE BOER WA, TYTGAT GNJ: Treatment of Helicobacter pylori infection. BMJ(2000) 320:31–34.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of therapeutic strategies.
   Google Scholar
• DE BOER WA: Strategies for therapy failures: choice of back-up regimen determined by primary treatment for H py/oriinfection. In: Helicobacter pylori. Basic Mechanisms to Clinical Cure 2000. Hunt RH, Tytgat GNJ (Eds.) Kluwer Academic Publishers, Dordrecht, The Netherlands (2000):609–621.
   Google Scholar
• •Major review on re-treatment.
   Google Scholar
• DE BOER WA, BORODY TJ: Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Digest. Liver Dis. (2000)32:673–675.
   Google Scholar
• VAN OIJEN AHAM, VERBEEK AL, JANSEN JBMJ, DE BOER WA: Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. Aliment Pharmacol The!: (2000) 14:991–999.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis of randomised trials with triple therapy.
   Google Scholar
• SABERI-FIROOZI M, MASSARAT S, ZARE S et al.: Effect of triple therapy or amoxicillin plus omeprazole or amoxicillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized controlled study. Am. J. Gastroenterol (1995) 90:1419–1423.
   PubMed Web of Science ®Google Scholar
• LERANG F, MOUM B, RAGNHILDSTVEIT E et al.: A comparison between omeprazole-based triple therapy and bismuth based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Am. j Gastroenterol (1997) 92:653–658.
   PubMed Web of Science ®Google Scholar
• KIM N, KOO MS, LIM SH, LEE KH: The resistance rate of H pylori to metronidazole and clarithromycin and its effect on 7-day triple therapy in Korea. Gastroenterology (1999) 116:A214.
   Web of Science ®Google Scholar
• STOLTENBERG M, MARTINY M, SORENSEN K, RUNGBY J, KROGFELT KA: Histochemical tracing of bismuth in Helicobacter pylori after in vitro exposure to bismuth citrate. Scam/. j Gastroenterol (2001) 36:144–148.
   PubMed Web of Science ®Google Scholar
• NWOKOLO CU, LEWIN JF, HUDSON M, POUNDER RE: Transmucosal penetration of bismuth particles in the human stomach. Gastroenterology (1992)102:163–167.
   PubMed Web of Science ®Google Scholar
• DE BOER WA, VAN ETTEN RJXM, SCHNEEBERGER PM, TYTGAT GNJ: A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am. j Gastroenterol (2000) 95:641–645.
   PubMed Web of Science ®Google Scholar
• ••First clinical results of the triple therapycapsule used alone.
   Google Scholar
• DE BOER WA: Towards monotherapy - what progress? First results with a new single triple capsule. In Hunt RH, Tytgat GNJ editors. Helicobacter pylori. Basic mechanisms to clinical cure (2000). Kluwer Academic Publishers, Dordrecht, The Netherlands (1998):456–461.
   Google Scholar
• •First clinical results of the triple therapy capsule + omeprazole.
   Google Scholar
• DE BOER WA, VAN ETTEN RJXM, VAN DE WOUW BAM, SCHNEEBERGER PM, VAN OIJEN AHAM, JANSEN JBMJ. Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole. Aliment Pharmacol Titer (2000)14:85–89.
   PubMed Web of Science ®Google Scholar
• LAINE L, HUNT RH, EL-ZIMAITY HMT, OSATO MS, SPENARD J. North-American randomized trial of single triple capsule (bismuth subcitrate, metronidazole, tetracycline) plus omeprazole vs. omeprazole. amoxicillin and clarithromycin for H pylori eradication. Gastroenterology (2001) 120:A580.
   Google Scholar
• ••The major randomised clinical trial of thetriple therapy capsule versus PPI-triple therapy.
   Google Scholar
• SPENARD A, O'MORAIN C, BUCKLEY M et al.: International trial of a single triple capsule of Bi subcitrate, metronidazole and tetracycline given with omeprazole in H pylori eradication: preliminary results. Abstract UEGW Amsterdam October (2001).
   Google Scholar
• DE BOER WA, TYTGAT GNJ: The best therapy for Helicobacter pylori infection. Should efficacy or side effect profile determine our choice? Land. Gast/venter-a (1995) 30:401–407.
   Google Scholar
• DE BOER WA, THYS JC, BORODY TJ, GRAHAM DY, CYMORAIN C, TYTGAT GNJ: Proposal for use of a standard side effect scoring system in studies exploring H pylori treatment regimens. Eur Gastroenterol Hepatol (1996) 8:641–643.
   PubMed Web of Science ®Google Scholar
• ROMANO M, IOVENE MR, MONTELLO E VITALE LM, DE SIMONE T, DEL VECCHIO BLANCO C: Pretreatment antimicrobial susceptibility testing in the eradication of Helicobacter pylori infection. Am. j Gastroenterol (2000) 95:3317–3318.
   PubMed Web of Science ®Google Scholar
• TORACCHIO S, CELLINI L, DI CAMPLI E et al.: Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol The!: (2000) 14:1639–1643.
   Google Scholar
• ROMANO M, IOVENE MR, MONTELLA F, VITALE LM, DE SIMONE T, DEL VECCHIO BLANCO C: Pretreatment antimicrobial susceptibility testing in the eradication of H pylori infection. Am. j Gastroenterol (2000) 95:3317–3318.
   PubMed Web of Science ®Google Scholar
• DORE MP, LEANDRO G, REALDI G, SEPULVEDA AR, GRAHAM DY: Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pyloritherapy. A meta-analytic approach. Dig. Dis. Sci. (2000) 45:68–76.
   PubMed Web of Science ®Google Scholar
• BREUER T, GRAHAM DY: Costs of diagnosis and treatment of Helicobacter pylori infection: When does choosing the treatment regimen based on susceptibility testing become cost-effective? Am. j Gastroenterol (1999) 94:725–729.
   Web of Science ®Google Scholar
• FENDRICK AM, CHEY WD, MARGARET N et al.: Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. Am. J. Med. (1999) 107:133–136.
   PubMed Web of Science ®Google Scholar
• CHEN W, CHO CH, CHADWICK VS: Novel and-Helicobacter pylori agents. Expert Opin. Titer Patents (2000) 10:1221-1232. Affiliation
   Google Scholar